Clopidogrel
- Generic Name
- Clopidogrel
- Brand Names
- Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)
- Drug Type
- Small Molecule
- Chemical Formula
- C16H16ClNO2S
- CAS Number
- 113665-84-2
- Unique Ingredient Identifier
- A74586SNO7
- Background
Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,
It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.
Clopidogrel was granted FDA approval on 17 November 1997.
- Indication
1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；
2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；
3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。
- Associated Conditions
- Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events
- Associated Therapies
- -
A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention
- Conditions
- Coronary ArteriosclerosisAcute Coronary Syndromes
- Interventions
- First Posted Date
- 2004-11-25
- Last Posted Date
- 2010-09-16
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 13619
- Registration Number
- NCT00097591
- Locations
- 🇺🇸
For more information regarding investigative sites for this trial, call 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST), Global Quintiles Study Line (1-866-615-4672) or speak with your physician, Indianapolis, Indiana, United States
Secondary Prevention of Small Subcortical Strokes Trial
- Conditions
- Cerebrovascular AccidentHypertension
- Interventions
- First Posted Date
- 2003-04-24
- Last Posted Date
- 2013-04-04
- Lead Sponsor
- University of British Columbia
- Target Recruit Count
- 3020
- Registration Number
- NCT00059306
- Locations
- 🇺🇸
Ohio State University, Division of Stroke, Columbus, Ohio, United States
🇺🇸Marshfield Clinic, Department of Neurology, Marshfield, Wisconsin, United States
🇺🇸Metrohealth Medical Center, Cleveland, Ohio, United States
A Trial of CS-747 (Prasugrel) Compared With Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention (PCI)
- Conditions
- Cardiovascular DiseasesHeart Diseases
- Interventions
- First Posted Date
- 2003-04-23
- Last Posted Date
- 2010-05-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 905
- Registration Number
- NCT00059215
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Boston, Massachusetts, United States
🇨🇦For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4599) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Victoria, British Columbia, Canada
Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
- Conditions
- Head and Neck CancerThromboembolism
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00020189
- Locations
- 🇺🇸
Center for Cancer Research, Bethesda, Maryland, United States
🇺🇸Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
The Inhibition of Platelet Antiaggregating Activity of Clopidogrel by Atorvastatin Detected by Erythromycin Breath Test: a Metabolic Inhibition of Hepatic Cytochrome P450-3A
- Conditions
- HypercholesterolemiaThrombosis
- First Posted Date
- 2000-02-14
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Registration Number
- NCT00004564
- Locations
- 🇺🇸
1G323 University Hospital, Box 0048 1500 E Medical Center Drive, Ann Arbor, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.